Pharmaceutical company Teva Pharmaceutical Industries (NYSE:TEVA) (TASE:TEVA) reported on Monday the election of Dipankar Bhattacharjee as president and chief executive officer of its global generic medicines group, USA.

Effective immediately, Bhattacharjee succeeds Sigurdur (Siggi) Olafsson, who will step down from his role and remain active with the company until officially retiring at the end of the first quarter of 2017 to ensure an orderly transition.

Most recently, Bhattacharjee has served as president and CEO of Teva Generics Europe, positions he has held since April 2013, as well as general manager, Teva UK Limited, position he has held since 2009.

Bhattacharjee previously worked as vice president commercial in both Europe and Asia-Pacific regions and corporate vice president and president, Asia Pacific Region, respectively, at Bausch + Lomb. He was part of Nestle SA and Bank of America at the start of his career.

For full-year 2016, the company expects revenues in the USD21.6bn-USD21.9bn range and Non-GAAP EPS in the USD5.10-USD5.20 range.